US 11,111,276 B2 · Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses

Abstract

Isolated mutant dengue virus E protein variants are disclosed. The variant comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has one or more amino acid residue substitutions at position corresponding to Asn8 (N8), Arg9 (R9), Val12 (V 12) and/or Glu13 (E13). The variant may comprise an amino acid sequence that is at least 90% identical to the SEQ ID NO: 1 and lack an infection-enhancing antibody-binding motif comprising the amino acid sequence of SEQ ID NO: 28 at domain I. An isolated nucleic acid sequence encoding the variant, a plasmid expressing the variant, a plasmid expressing a virus-like particle comprising the variant, a DNA vaccine, and a method of detecting the presence of a dengue virus in a biological sample are also disclosed.

Claims19

Dependent claims

A method for neutralizing and protecting against one or more dengue virus serotypes infection, and/or for neutralizing a dengue virus, reducing, alleviating antibody dependent enhancement of dengue virus infection, and/or increasing survival rate in a subject in need thereof, comprising:

administering to the subject in need thereof a therapeutically effective amount of a plasmid expressing a mutant dengue virus E protein comprising an amino acid sequence that is at least 80% identical to SEQ ID NO;
1, wherein the mutant dengue virus E protein has one or more amino acid residue substitutions at position corresponding to Asn8, Arg9, Val12, and/or Glu13 of SEQ ID NO:
1.

Dependencies are inferred from the claim text.

Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses

Life of this patent

Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses

Life of this patent

Abstract

Claims19